Literature DB >> 22421431

In vivo and in vitro evaluation of Cy5.5 conjugated epidermal growth factor receptor binding peptide.

Min-Hee Jeong1, Kisu Kim, Eun-Mi Kim, Su-Jin Cheong, Chang-Moon Lee, Hwan-Jeong Jeong, Dong Wook Kim, Seok Tae Lim, Myung-Hee Sohn, Junho Chung.   

Abstract

The epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor and plays an important role in carcinogenesis. In this study, the epidermal growth factor receptor binding peptide (EGBP) was identified using a phage display method and evaluated in U87MG cells in order to investigate the possibility to target the EGFR using an optical imaging system. Cyanine dye 5.5 (Cy5.5) was conjugated with EGBP-GGG-SC, EGBP-AOC-SC, and EGBP-AM2BA-SC. Cellular binding study of EGBP-Linker-Cy5.5 conjugates or (125)I-EGBP-Linker compounds was performed in U87MG cells. Optical imaging studies were performed in U87MG bearing mice. Three of seven clones from the 12-mer peptide library showed a specific binding affinity to rhEGFR, and they encoded the same 12 amino acid peptide sequence, FPMFNHWEQWPP. Confocal images show that the fluorescent signal of EGBP-Linker-Cy5.5 conjugates was decreased in the order: EGBP-AOC-Cy5.5≫EGBP-AM2BA-Cy5.5>EGBP-GGG-Cy5.5. EGBP-AOC-Cy5.5 appeared in cell cytoplasm and surface, and it was inhibited by free EGBP apparently. The cellular binding of EGBP-AOC-Cy5.5 exhibited a higher average radiance value than EGBP-GGG-Cy5.5 and EGBP-AM2BA-Cy5.5. Among various (125)I-EGBP-Linker compounds, EGBP-GGG showed a higher binding than other compounds. However, uptake of (125)I-EGBP-AOC was clearly inhibited by free EGBP in inhibition study. In an in vivo study, the fluorescent signal of EGBP-AOC-Cy5.5 treated mouse was mainly detected in the tumor and kidney. Among the three derivatives, EGBP-AOC-Cy5.5 was the optimized optical imaging agent for U87MG EGFR positive tumors in the animal model. This study demonstrated the EGBP-Linker-Cy5.5 conjugates may be useful as a potential EGFR target optical probe.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22421431     DOI: 10.1016/j.nucmedbio.2012.01.001

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  4 in total

Review 1.  High-Throughput Approaches to the Development of Molecular Imaging Agents.

Authors:  Lina Y Hu; Kimberly A Kelly; Julie L Sutcliffe
Journal:  Mol Imaging Biol       Date:  2017-04       Impact factor: 3.488

Review 2.  Tumor-targeting peptides from combinatorial libraries.

Authors:  Ruiwu Liu; Xiaocen Li; Wenwu Xiao; Kit S Lam
Journal:  Adv Drug Deliv Rev       Date:  2016-05-19       Impact factor: 15.470

3.  A High-Affinity Repebody for Molecular Imaging of EGFR-Expressing Malignant Tumors.

Authors:  Misun Yun; Dong-Yeon Kim; Joong-Jae Lee; Hyeon-Sik Kim; Hyung-Seok Kim; Ayoung Pyo; Yiseul Ryu; Tae-Yoon Kim; Jin Hai Zheng; Su Woong Yoo; Hoon Hyun; Gyungseok Oh; Jaeho Jeong; Myeongju Moon; Jung-Hyun Min; Seong Young Kwon; Jung Young Kim; Euiheon Chung; Yeongjin Hong; Wansik Lee; Hak-Sung Kim; Jung-Joon Min
Journal:  Theranostics       Date:  2017-06-25       Impact factor: 11.556

4.  Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting.

Authors:  J P Tiernan; S L Perry; E T Verghese; N P West; S Yeluri; D G Jayne; T A Hughes
Journal:  Br J Cancer       Date:  2013-01-15       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.